Cogent Biosciences, Inc. (COGT) stock
COGTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$27.85+0.41 (+1.49%)
Close on Nov 17, 2026Market cap $4.83BP/E –Yield –
Cogent Biosciences cash
Cash and short-term investments held at the end of each period.
Cogent Biosciences's cash was $792.30M at Jun 30, 2026. For fiscal 2025 it was $900.77M, up 213.8% from the year before. The highest annual figure on record is $900.77M in fiscal 2025.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $900.77M | +213.8% |
| FY2024 | Dec 31, 2024 | $287.08M | +8.0% |
| FY2023 | Dec 31, 2023 | $265.71M | +2.0% |
| FY2022 | Dec 31, 2022 | $260.53M | +17.9% |
| FY2021 | Dec 31, 2021 | $220.94M | -9.2% |
| FY2020 | Dec 31, 2020 | $243.45M | +529.4% |
| FY2019 | Dec 31, 2019 | $38.68M | -32.1% |
| FY2018 | Dec 31, 2018 | $56.93M | +34.6% |
| FY2017 | Dec 31, 2017 | $42.29M | -0.7% |
| FY2016 | Dec 31, 2016 | $42.58M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $792.30M | +233.1% |
| Q1 FY2026 | Mar 31, 2026 | $866.38M | +252.7% |
| Q4 FY2025 | Dec 31, 2025 | $900.77M | +213.8% |
| Q3 FY2025 | Sep 30, 2025 | $390.89M | +16.5% |
| Q2 FY2025 | Jun 30, 2025 | $237.85M | -34.5% |
| Q1 FY2025 | Mar 31, 2025 | $245.66M | -43.6% |
| Q4 FY2024 | Dec 31, 2024 | $287.08M | +8.0% |
| Q3 FY2024 | Sep 30, 2024 | $335.52M | +20.2% |
| Q2 FY2024 | Jun 30, 2024 | $363.22M | +10.3% |
| Q1 FY2024 | Mar 31, 2024 | $435.74M | +96.7% |
| Q4 FY2023 | Dec 31, 2023 | $265.71M | +2.0% |
| Q3 FY2023 | Sep 30, 2023 | $279.04M | -3.9% |
| Q2 FY2023 | Jun 30, 2023 | $329.40M | +0.8% |
| Q1 FY2023 | Mar 31, 2023 | $221.52M | +15.2% |
| Q4 FY2022 | Dec 31, 2022 | $260.53M | +17.9% |
| Q3 FY2022 | Sep 30, 2022 | $290.35M | +42.2% |
| Q2 FY2022 | Jun 30, 2022 | $326.82M | +49.0% |
| Q1 FY2022 | Mar 31, 2022 | $192.30M | -17.1% |
| Q4 FY2021 | Dec 31, 2021 | $220.94M | -9.2% |
| Q3 FY2021 | Sep 30, 2021 | $204.14M | +56.2% |
| Q2 FY2021 | Jun 30, 2021 | $219.36M | +870.7% |
| Q1 FY2021 | Mar 31, 2021 | $231.99M | +651.8% |
| Q4 FY2020 | Dec 31, 2020 | $243.45M | +529.4% |
| Q3 FY2020 | Sep 30, 2020 | $130.68M | +177.2% |
| Q2 FY2020 | Jun 30, 2020 | $22.60M | -60.4% |
| Q1 FY2020 | Mar 31, 2020 | $30.86M | -48.9% |
| Q4 FY2019 | Dec 31, 2019 | $38.68M | -32.1% |
| Q3 FY2019 | Sep 30, 2019 | $47.14M | -6.8% |
| Q2 FY2019 | Jun 30, 2019 | $57.12M | +18.9% |
| Q1 FY2019 | Mar 31, 2019 | $60.37M | +79.1% |
| Q4 FY2018 | Dec 31, 2018 | $56.93M | +34.6% |
| Q3 FY2018 | Sep 30, 2018 | $50.55M | +58.2% |
| Q2 FY2018 | Jun 30, 2018 | $48.04M | +47.8% |
| Q1 FY2018 | Mar 31, 2018 | $33.71M | -2.3% |
| Q4 FY2017 | Dec 31, 2017 | $42.29M | -0.7% |
| Q3 FY2017 | Sep 30, 2017 | $31.95M | – |
| Q2 FY2017 | Jun 30, 2017 | $32.51M | – |
| Q1 FY2017 | Mar 31, 2017 | $34.49M | – |
| Q4 FY2016 | Dec 31, 2016 | $42.58M | – |
See a number that looks wrong?